Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CPA1 | P15085 | 2/20 | 0.42 |
| ▸ | CPA3 | P15088 | 2/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.42 |
| ▸ | CPB1 | P15086 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20021560 | 0.88 | MTNR1A (0.57) | CYP1A2PPARGMTNR1AMTNR1BMAPT | |
| SCHEMBL8825845 | 0.87 | POLB (0.50) | POLBCYP1A2SMN1; SMN2PPARGALDH1A1 | |
| SCHEMBL19483359 | 0.79 | CYP1A2 (0.55) | CYP1A2NPC1RAB9AMAPTCPA1 | |
| SCHEMBL1709341 | 0.79 | CYP1A2 (0.60) | CYP1A2PPARGMAPTCPA1CPA3 | |
| SCHEMBL19483390 | 0.79 | CYP1A2 (0.55) | CYP1A2NPC1RAB9AMAPTCPA1 | |
| SCHEMBL683352 | 0.75 | NPSR1 (0.55) | POLBNPC1RAB9AMAPTMME | |
| SCHEMBL684246 | 0.75 | NPSR1 (0.55) | POLBNPC1RAB9AMAPTMME | |
| Hydrochloric Acid SCHEMBL4881121 | 0.74 | POLB (0.49) | POLBCYP1A2SMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL8462971 | 0.73 | MDM2 (0.55) | POLBCYP1A2NPC1RAB9AMAPT | |
| SCHEMBL1516186 | 0.73 | RIPK1 (0.71) | POLBCYP1A2SMN1; SMN2ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220211675-A1 | TIE-2 ACTIVATORS TARGETING THE SCHLEMM'S CANAL | EyePoint, Inc. | 2022-07-07 | — | — | US | disclosed |
| US-11253502-B2 | Tie-2 activators targeting the Schlemm's canal | EyePoint Pharmaceuticals, Inc. (US) | 2022-02-22 | — | — | US | disclosed |
| US-20200361926-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2020-11-19 | — | — | US | disclosed |
| US-20200338048-A1 | TIE-2 ACTIVATORS TARGETING THE SCHLEMM'S CANAL | EyePoint, Inc. | 2020-10-29 | — | — | US | disclosed |
| US-20190076405-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASASIS OF CANCER CELLS | EyePoint Pharmaceuticals, Inc. | 2019-03-14 | — | — | US | disclosed |
| US-10220048-B2 | Compositions and methods for treating ocular diseases | AERPIO THERAPEUTICS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-9949956-B2 | Compounds, compositions, and methods for preventing metastasis of cancer cells | AERPIO THERAPEUTICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9949956-B2 | Compounds, compositions, and methods for preventing metastasis of cancer cells | AERPIO THERAPEUTICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20180092883-A1 | PHOSPHATASE INHIBITORS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2018-04-05 | — | — | US | disclosed |
| US-20180037579-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | EyePoint Pharmaceuticals, Inc. | 2018-02-08 | — | — | US | disclosed |
| US-20140378445-A9 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2014-12-25 | — | — | US | disclosed |
| US-8883832-B2 | Compounds, compositions, and methods for preventing metastasis of cancer cells | AERPIO THERAPEUTICS INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20140288134-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | AERPIO THERAPEUTICS INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140275103-A1 | Compositions, formulations and methods for treating ocular diseases | AERPIO THERAPEUTICS INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140249100-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | AERPIO THERAPEUTICS INC. (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140242026-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | EyePoint, Inc. | 2014-08-28 | — | — | US | disclosed |
| US-20140179693-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | SHALWITZ ROBERT (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140066458-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2014-03-06 | — | — | US | disclosed |
| US-20120129847-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | EyePoint Pharmaceuticals, Inc. | 2012-05-24 | — | — | US | disclosed |
| US-20110268694-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129847-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | FLT4, VEGFA, AQP3 | POLB 1846/4885CYP1A2 4824/4885SMN1; SMN2 4549/4885 |
| US-20140242026-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | EPCAM, CD44, CDH1 | POLB 2724/4885CYP1A2 3978/4885SMN1; SMN2 3113/4885 |
| US-20140066458-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | POLB 3185/4885CYP1A2 4581/4885SMN1; SMN2 2103/4885 |
| US-20220211675-A1 | TIE-2 ACTIVATORS TARGETING THE SCHLEMM'S CANAL | TIE1, TEK, TGFB2 | POLB 4242/4885CYP1A2 4546/4885SMN1; SMN2 4631/4885 |
| US-20140288134-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | FLT4, VEGFA, AQP3 | POLB 1846/4885CYP1A2 4824/4885SMN1; SMN2 4549/4885 |
| US-10220048-B2 | Compositions and methods for treating ocular diseases | VEGFA, FLT4, AQP3 | POLB 2865/4885CYP1A2 4763/4885SMN1; SMN2 4723/4885 |
| US-20140378445-A9 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, EPCAM | POLB 2776/4885CYP1A2 4700/4885SMN1; SMN2 1811/4885 |
| US-20140275103-A1 | Compositions, formulations and methods for treating ocular diseases | TIE1, TEK, KDR | POLB 2429/4885CYP1A2 4131/4885SMN1; SMN2 3732/4885 |
| US-11253502-B2 | Tie-2 activators targeting the Schlemm's canal | TIE1, TEK, TGFB2 | POLB 4242/4885CYP1A2 4546/4885SMN1; SMN2 4631/4885 |
| US-20140249100-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | EPCAM, CD44, CDH1 | POLB 2724/4885CYP1A2 3978/4885SMN1; SMN2 3113/4885 |
| US-20190076405-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASASIS OF CANCER CELLS | TSG101, MMP8, EPCAM | POLB 2164/4885CYP1A2 3083/4885SMN1; SMN2 2100/4885 |
| US-20110268694-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | POLB 3185/4885CYP1A2 4581/4885SMN1; SMN2 2103/4885 |
| US-20200338048-A1 | TIE-2 ACTIVATORS TARGETING THE SCHLEMM'S CANAL | TIE1, TEK, TGFB2 | POLB 4242/4885CYP1A2 4546/4885SMN1; SMN2 4631/4885 |
| US-20140179693-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, EPCAM | POLB 2776/4885CYP1A2 4700/4885SMN1; SMN2 1811/4885 |
| US-20180037579-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | FLT4, VEGFA, AQP3 | POLB 1846/4885CYP1A2 4824/4885SMN1; SMN2 4549/4885 |
| US-20200361926-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | POLB 2429/4885CYP1A2 4131/4885SMN1; SMN2 3732/4885 |
| US-20180092883-A1 | PHOSPHATASE INHIBITORS FOR TREATING OCULAR DISEASES | PPM1G, PPM1F, PPM1A | POLB 1897/4885CYP1A2 4820/4885SMN1; SMN2 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.